Published January 03, 2025 11:17
This article investigates the efficiency of covalent drugs on the oncogenic protein KRasG12C. Different molecular modifications were used to understand the role of non-covalent and covalent interactions in inhibition. Our results show that the ARS-1620 compound scaffold is not essential for KRASG12C inhibition and that warheads only affect covalent reactions. This analysis may help to design more effective covalent inhibitors in the future.
